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Cerebrospinal fluid amyloid-beta 1–42 (Ab1–42) and phosphorylated Tau at position 181 (pTau181) are biomar-
kers of Alzheimer’s disease (AD). We performed an analysis and meta-analysis of genome-wide association
study data on Ab1–42 and pTau181 in AD dementia patients followed by independent replication. An association
was found between Ab1 – 42 level and a single-nucleotide polymorphism in SUCLG2 (rs62256378)
(P 5 2.5310212). An interaction between APOE genotype and rs62256378 was detected (P 5 9.5 3 1025), with
the strongest effect being observed in APOE-14 noncarriers. Clinically, rs62256378 was associated with rate
of cognitive decline in AD dementia patients (P 5 3.1 3 1023). Functional microglia experiments showed that
SUCLG2 was involved in clearance of Ab1–42.
INTRODUCTION
Alzheimer’s disease (AD) is a complex disorder in which several
pathways contribute to pathology and clinical phenotype. Delin-
eation of each pathological pathway and identification of the
factors which modulate them are crucial for the development
of effective treatment. Information on individual pathological
pathways is provided by biomarkers. In AD, cerebrospinal
fluid (CSF) levels of Ab1 – 42 and phosphorylated Tau (pTau)
reflect cerebral amyloid deposition and tau-related neurodegen-
eration, respectively. However, many of the biological factors
that influence these core AD pathways remain elusive.
Research has shown that AD risk genes contribute to CSF
marker variance (1–4). However, genes may also exist that
affect CSF markers without conferring disease susceptibility.
These genes may be promising candidates for modulation of
the disease process.
The aim of the present study was to identify genetic factors
related to heterogeneity in pathological pathways involved in
amyloid deposition and tau-related neurodegeneration—as
manifested through CSF Ab1 – 42 and pTau levels—and which
might influence the clinical course of AD. To achieve this, we
performed a four-step investigation involving analysis and
meta-analysis of data from genome-wide association studies
(GWASs) of these two CSF biomarkers; replication of our top
findings in an independent sample; and specific analyses and
functional experiments to follow-up promising findings. In con-
trast to previous GWAS of CSF biomarkers (1,4,5), the present
GWAS was restricted to patients with dementia secondary to
AD only in order to enrich for genetic effects occurring after
disease onset.
RESULTS
Study design
We analyzed GWAS data on CSF biomarkers Ab1 – 42 and Tau
phosphorilated at position 181 (pTau181) from three independent
AD cohorts (Bonn1CSF, n ¼ 113; Bonn2CSF, n ¼ 167; ADNI,
n ¼ 83). The resulting data were then combined in a
meta-analysis. The three GWAS cohorts are described in detail
in Materials and Methods and Table 1. In all three cohorts, the
CSF biomarkers Ab1 – 42 and pTau181 showed a normal distribu-
tion (Supplementary Material, Figs S1 and S2).
For the replication step, we selected single-nucleotide poly-
morphisms (SNPs) that showed consistent allele direction
across all three GWAS, which modulated either Ab1 – 42 or
pTau181 with P,5 × 1026, and which showed consistent
allele direction across all studies. These 30 SNPs, together
with 10 SNPs representing known AD susceptibility genes,
were then genotyped in an independent sample of 515 AD
dementia patients (Amsterdam Dementia Cohort, ADC).
These 40 SNPs represented a total of 39 loci. Two SNPs
showing association with CSF levels of Ab1 – 42 in the GWAS
meta-analysis were replicated in the ADC, i.e. rs429358 at the
APOE locus and rs62256378 at a novel locus containing the
SUCLG2 gene. The ADC sample is described in detail in Mate-
rials and Methods and Table 1. In the ADC cohort, the CSF bio-
markers Ab1 – 42 and pTau181 showed a normal distribution
(Supplementary Material, Figs. S1 and S2).
Since these two replicated loci both modulated Ab1 – 42 levels
in the CSF, we explored a possible genetic interaction, since this
might suggest a biological link between the two loci. We also
investigated whether rs62256378 (i) confers AD risk, using a
case–control sample and (ii) has a possible effect on cognitive
decline in AD dementia patients, using prospective data on Mini-
Mental State Examination (MMSE) scores. The samples used in
these two analyses are described in detail in Materials and
Methods.
Functional experiments were then performed to elucidate the
functional role of SUCGL2 in Ab1 – 42 homeostasis. First, the
cellular distribution of SUCLG2 was examined in postmortem
human brain tissue from individuals who had died from non-
neurological disease. Secondly, to follow-up our finding con-
cerning genetic interaction with APOE, the effect of APOE-14
carrier status on the protein expression of SUCLG2 was investi-
gated using protein extracts from human AD and control post-
mortem frontal cortex. Thirdly, the role of SUCLG2 in
microglial Ab1 – 42 phagocytosis was analyzed by reducing
SUCLG2 expression through siRNA approaches.
GWAS meta-analysis
Meta-analysis of the three GWAS yielded genome-wide infla-
tion factors of l ¼ 1.05 for Ab1 – 42 and l ¼ 1.03 for pTau181
(Supplementary Material, Fig. S3). After l-adjustment, a
genome-wide significant association was observed between
APOE-14 (rs429358) and Ab1 – 42 (P ¼ 1.8 × 10210), thus con-
firming published data (Table 2) (1,4,5). A total of 335 SNPs
were below the threshold of genome-wide significance but had
a promising P-value of ,5 × 1026 (Fig. 1). Of these, 163
showed consistent allele direction across all three GWAS.
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Replication and meta-analysis of combined data
Thirty-five of the 40 SNPs included in the replication step were
successfully genotyped (Supplementary Material, Table S1).
The replication step revealed a strong association between
rs429358 (APOE-14) and Ab1 – 42 levels (P ¼ 1.1 × 1025,
b ¼ 20.7+ 0.015, Table 2). The units used to express the
effect size of the SNPs (b+SE) are standardized. This associ-
ation became stronger in a meta-analysis of the combined
GWAS and replication data (P ¼ 4.3 × 10217, b ¼ 20.4+
0.05, Table 2).
The second strongest replication signal was for association
between an SNP on chromosome 3p14.1 [rs62256378, minor
allele frequency (MAF) ¼ 6.1%], and Ab1–42 levels (P ¼ 1.9 ×
1026, b ¼ 0.61+0.13; Supplementary Material, Fig. S4). The
meta-analysis of the GWAS and replication data generated a
highly significant finding (P ¼ 2.5 × 10212, b ¼ 0.71+0.10),
with the low-frequency allele being associated with higher
Ab1–42 levels and showing an effect size (standardized units for
b+SE) that was larger than that of APOE-14. Since rs622
56378 was imputed, we genotyped this SNP in 264 individuals
from the GWAS step for whom DNA was available. The genotyp-
ing of rs62256378 using Sequenom technology revealed a con-
cordance between imputed and experimental genotypes of
.99%,demonstrating thevalidityof the imputedrs62256378gen-
otypes in the GWAS step (the results of the statistical calculations
that involved imputed and experimental genotypes are provided in
Supplementary Material, Table S2).
With the exception of APOE, none of the known AD suscep-
tibility genes showed genome-wide significant association with
Ab1 – 42 or pTau181 levels in the meta-analysis of the three
GWAS and the replication sample (Table 3). Both CD2AP
(rs9349407) and APOE (rs429358) showed a nominally signifi-
cant association with increased pTau181 levels (P ¼ 0.031 and
0.029, respectively).
Effect of rs62256378 on AD risk
In the case–control analysis, no association was found between
rs62256378andAD risk (P¼ 0.8, OR¼ 1.03,95% CI 0.79–1.27).
However, we cannot exclude the possibility that an AD
association might be detected in a larger case–control sample.
To test this, we obtained Stage I association data for rs6225
6378 from the case–control meta-analysis study conducted by
the International Genomics of Alzheimer’s Project (IGAP) (6).
Here, the SNP rs62256378 showed no association with AD
risk in either the complete Stage I analysis (P ¼ 0.7, OR ¼
0.98, 95% CI 0.91–1.06) or the stratum of APOE-14 noncarrier
(P ¼ 0.7, OR ¼ 1.02, 95% CI 0.91–1.13).
Genetic interaction between rs429358 and rs62256378
Both of the presently replicated loci modulated Ab1 – 42 levels.
APOE-14 was associated with lower Ab1 – 42 levels, and the
minor allele A of rs62256378 was associated with higher
Ab1 – 42 levels. Investigation of a possible interaction between
the two association signals revealed strong evidence for allelic
interaction (P ¼ 9.5 × 1025, Table 4). The effect of the minor
allele A of rs62256378 varied substantially depending on
APOE-14 carrier–noncarrier status (Table 5). The strongestT
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Table 2. Summary of GWAS, replication and overall meta-analysis for SNPs with P , 5 × 1026 and the same effect direction in all three GWAS samples
GWAS Replication Combined analysis
Trait rsa chrb bpc EAd/OAe bf SEg dirh P-adji rsa EAd/OAe MAFj bk SEg Pl EAd/OAe dirm bn SEo Pp
Ab1 – 42 2-45978647 2 45 978 642 G/GT 20.382 0.08 222 2.1 × 1026 rs6753292q T/C 0.251 0.01 0.08 0.91 G/GT +2 20.18 0.05 1.1 × 1023
rs374159788 2 172 759 319 A/AGT 0.608 0.12 +++ 1.6 × 1026 rs34737109q A/G 0.383 20.08 0.07 0.23 A/AGT +2 0.07 0.06 0.21
rs62256378 3 67 457 033 A/G 0.89 0.17 +++ 3.0 × 1027 rs62256378 A/G 0.061 0.61 0.13 1.9 × 1026 A/G 222 0.71 0.10 2.5 × 10212
rs893703 3 139 250 649 G/A 0.639 0.13 +++ 1.2 × 1026 rs4407373q T/G 0.099 20.05 0.11 0.68 G/A +2 0.25 0.08 3.2 × 1023
rs12493397 3 165 284 889 A/G 20.422 0.09 222 3.9 × 1026 rs2222464q C/T 0.274 20.02 0.07 0.76 A/G 222 20.18 0.06 1.2 × 1023
rs388575 4 107 973 286 C/T 20.518 0.09 222 1.5 × 1028 rs388575 C/T 0.252 0.05 0.07 0.50 C/T 2+ 20.18 0.06 1.4 × 1023
6-63065777 6 63 065 777 A/AAAT 1.241 0.20 +++ 2.9 × 1029 rs12527308q T/C 0.15 0.09 0.09 0.31 A/AAAT ++ 0.28 0.08 7.0 × 1024
rs2258946 10 93 624 672 A/G 0.521 0.10 +++ 6.6 × 1027 rs2258946 T/C 0.145 20.10 0.09 0.29 A/G +2 0.17 0.07 1.1 × 1022
rs61023801 13 91 828 308 G/A 1.084 0.21 +++ 4.7 × 1027 rs74922937q A/G 0.026 0.02 0.20 0.92 G/A ++ 0.52 0.14 3.0 × 1024
APOE-14 (rs429358) 19 45 411 941 14/14(2) 20.48 0.07 222 1.8 × 10210 APOE-14 (rs429358) 14/14(2) 0.442 20.70 0.15 1.1 × 1025 14/14(-) 22 20.40 0.05 4.3 × 10217
pTau181 rs72804029 2 59 273 581 T/C 20.804 0.17 222 2.7 × 1026 rs72804029 T/C 0.089 0.04 0.13 0.73 T/C 2+ 20.26 0.10 1.0 × 1022
rs313541 4 25 263 478 G/A 0.501 0.11 +++ 2.8 × 1026 rs313561q G/A 0.192 20.06 0.09 0.50 G/A +2 0.16 0.07 1.3 × 1022
rs73276571 5 120 616 307 A/G 0.66 0.14 +++ 1.8 × 1026 rs73276571 A/G 0.082 20.20 0.13 0.13 A/G +2 0.22 0.10 2.4 × 1022
rs4896367 6 138 807 281 C/T 0.493 0.10 +++ 1.4 × 1026 rs4896367 C/T 0.268 20.04 0.08 0.62 C/T +2 0.16 0.06 1.1 × 1022
rs9397718 6 154 753 469 C/T 0.397 0.08 +++ 3.4 × 1026 rs6911312q C/A 0.356 20.01 0.07 0.90 C/T +2 0.18 0.06 1.4 × 1023
rs9397794 6 155 575 942 A/G 0.449 0.09 +++ 2.6 × 1026 rs9397794 A/G 0.245 20.01 0.08 0.88 A/G +2 0.18 0.06 3.0 × 1023
rs77131199 10 26 798 222 A/G 1.484 0.32 +++ 3.6 × 1026 rs77131199 A/G 0.037 0.01 0.18 0.95 A/G ++ 0.37 0.16 1.7 × 1022
rs12418935 11 11 863 410 A/G 0.615 0.12 +++ 1.1 × 1026 rs12418935 A/G 0.107 20.05 0.12 0.65 A/G +2 0.26 0.09 2.1 × 1023
rs7304039 12 108 736 352 A/G 0.414 0.08 +++ 7.9 × 1027 rs7304039 A/G 0.295 20.07 0.08 0.34 A/G +2 0.15 0.06 6.9 × 1023
rs4942417 13 32 887 389 C/A 0.441 0.09 +++ 2.1 × 1026 rs4942417 C/A 0.154 20.08 0.10 0.42 C/A +2 20.19 0.07 3.6 × 1023
18-13887179 18 13 887 179 GAA/G 20.775 0.14 222 5.0 × 1028 rs7230126q C/T 0.317 0.03 0.07 0.67 GAA/G 2+ 20.14 0.06 3.1 × 1022
rs3794851 18 74 709 351 C/G 1.050 0.22 +++ 3.4 × 1026 rs3794851 C/G 0.046 20.01 0.16 0.93 C/G +2 0.36 0.13 6.7 × 1023
rs149933701 19 6 636 839 C/T 10.678 0.22 +++ 1.6 × 1026 rs61111347q A/G 0.039 20.08 0.17 0.63 C/T +2 0.36 0.14 8.0 × 1023
rs11700591 21 41 507 695 C/T 0.723 0.13 +++ 9.9 × 1028 rs11700591 C/T 0.069 20.02 0.13 0.89 C/T +2 20.35 0.09 2.3 × 1024
X-118495317 X 118 495 317 C/CT 0.619 0.12 +++ 3.0 × 1027 rs217969q T/A 0.256 0.04 0.07 0.50 C/CT ++ 0.18 0.06 2.0 × 1023
r2-values for proxy SNPs were computed on the basis of 1000 Genomes reference data, May 2012 release, CEU sample. GWAS, genome-wide association study.
ars number.
bChromosome.
cPhysical position in base pairs, according to dbSNP build 37.
dEffect allele: allele for which the effect estimate is reported.
eOther allele.
fEffect estimate (fixed effects meta-analysis) for Step 1 meta-analysis.
gCorresponding standard error.
hEffect directions in the three initial studies.
iLambda-adjusted P-value (fixed effects meta-analysis), GWAS meta-analysis.
jMinor allele frequency.
kEffect estimate from regression analysis. Represents changes in Ab1 – 42 or pTau181 levels in standard deviations per minor allele.
lP-value of regression analysis.
mEffect directions for Step 1 (joint direction) and replication analysis.
nEffect estimate (fixed effects meta-analysis) GWAS meta-analysis plus replication.
oCorresponding standard error.
pP-value (fixed effects meta-analysis) GWAS meta-analysis plus replication.
qProxy SNP supporting the signal of the GWAS.
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effect of rs62256378-A in terms of elevation of Ab1 – 42 levels
was observed in APOE-14 noncarriers (P ¼ 1.5 × 1028, b ¼
0.97+ 0.17, Table 5; Supplementary Material, Fig. S5). The
units used to express the effect of the SNPs (b+SE) are standar-
dized. In heterozygous APOE-14 carriers, the effect remained
significant, although the level of significance was reduced
(P ¼ 1.5 × 1023, b ¼ 0.35+ 0.11, Table 5; Supplementary
Material, Fig. S5). In APOE-14 homozygotes, no significant
effect was detectable for rs62256378-A (P ¼ 0.84). This
finding was supported by the consistent pattern of interaction
observed across all four sub-samples (Table 5). However, the
study-specific effect estimates for rs62256378 (Table 5) indicate
substantial heterogeneity (I2 ¼ 72%, P ¼ 9.9 × 1024 with
x2-test for heterogeneity). This heterogeneity was driven by
the Bonn1CSF sample, which had a markedly higher effect esti-
mate than the other studies. Interestingly, our signal was not
driven by this sub-study, since meta-analysis of the remaining
three studies also yielded genome-wide significance for
rs62256378 (P ¼ 2.2 × 1029, b ¼ 0.64+ 0.11).
Rs62256378 and cognitive decline
The SNP rs62256378-A significantly attenuated cognitive
decline in AD dementia patients (P ¼ 3.1 × 1023, b ¼ 0.32+
0.12, Table 6; Supplementary Material, Fig. S6). After stratifica-
tion for APOE genotype, this effect was significant in APOE-14
noncarriers (P ¼ 0.021, b ¼ 0.32+ 0.16, Table 6). A non-
significant trend was observed in heterozygous APOE-14 car-
riers (P ¼ 0.07, b ¼ 0.31+ 0.21). No evidence was found for
interaction between SUCLG2 (rs62256378) and APOE genotype
(P ¼ 0.456).
Conditional analysis of the SUCLG2 locus
This marker is located within a recombination hotspot. This
hotspot defines two linkage disequilibrium blocks that span
several exons of SUCLG2 on chromosome 3p14.1 (Supplemen-
tary Material, Fig. S4). Conditional analysis showed that all add-
itional signals in this region were dependent on rs62256378
(Supplementary Material, Table S4).
Functional investigation of the role of SUCLG2
Immunohistochemistry revealed that SUCLG2 expression was
mainly confined to microglial cells (7) in the postmortem brains
of AD dementia patients and age-matched controls (Fig. 2A
and B). The strongest association between rs62256378 and
higher Ab1–42 levels was observed in APOE-14 noncarriers. To
determine whether APOE status influenced SUCLG2 levels,
SUCLG2 protein levels were analyzed in human postmortem
samples from the frontal cortex, a brain region affected at an
early stage of AD. Here, ApoE3/3 carriers showed significantly
higher SUCLG2 levels compared with ApoE3/4 carriers
(Fig. 2C). Controls in turn showed the lowest levels, reinforcing
the hypothesis that rs62256378 may influence the disease course
in AD, rather than overall disease risk. SUCLG2 levels in micro-
glial cells were then lowered using various siRNA approaches
(Supplementary Material, Fig. S7). Decreasing microglial
SUCLG2 compromised Ab1 – 42 phagocytosis in a time-
dependent manner (Fig. 2D).
DISCUSSION
The present study demonstrated that genetic variation in
SUCLG2 modulated Ab1 – 42 levels in AD dementia patients.
Figure 1.Genome-wide signal intensity (Manhattan) plots. (A) Results for the association with CSF Ab1 – 42. (B) Results for the association with CSF pTau181. Both
plots show the individualP-values against genomic position. Chromosome number is shown on the x-axis. The results within each chromosome are plotted left to right,
with left being the P-terminal end of the corresponding chromosome. Horizontal dashed lines indicate a P-value threshold of 5 × 1028 (i.e. genome-wide signifi-
cance). Green dots depict single-nucleotide polymorphisms with genome-wide significance in the genome-wide association study step.
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Furthermore, we found that SUCLG2 was associated with AD
clinical course, as measured by change in MMSE over time.
Despite substantial evidence for heterogeneity in the effect
of rs62256378, the stronger effect estimate observed in
Bonn1CSF does not call the validity of our initial result for
rs62256378 into question, since the overall signal was not deter-
mined by Bonn1CSF; the meta-analysis that excluded this
sample also demonstrated genome-wide significance for
rs62256378 (P ¼ 2.2 × 1029, b ¼ 0.64+ 0.11).
To our knowledge, no previous genetic or biological study has
implicated SUCLG2 in AD. The negative result of our case–
control analysis suggests that this gene does not confer AD sus-
ceptibility, which would explain why it has not been identified in
previous case–control GWAS of AD. Possible reasons for the
failure of previous GWAS of CSF markers to identify
SUCLG2 are 3-fold. First, they included unaffected subjects
and individualswithmildcognitive impairment (MCI).Secondly,
they analyzed non-imputed datasets. In this regard, we computed
r2 values for rs62256378 with SNPs from the 1000 Genomes
project data, release May 2012. Only five SNPs (rs76856038,
rs76856038, rs80028595, rs115298081 and rs74727963)
showed r2 values of .0.50 with rs62256378, and none of
these are included in the Illumina 550K or Omni marker
panels. Thirdly, APOE status was not used as a covariate in the
analyses. In contrast, analysis in the present study was restricted
to AD dementia patients only, genetic data were imputed, and
APOE status was included as a covariate.
Our data also confirmed the previously reported association
between the APOE locus and Ab1 – 42 levels. Interestingly, the
effect of SUCLG2 was mainly observed in APOE-14 noncar-
riers. This suggests that SUCLG2 and APOE converge in their
effect on Ab1 – 42 levels in some, as yet unidentified, common
biological pathway.
The effect of SUCLG2 on Ab1 – 42 levels was surprisingly
high, since we did not expect to identify a novel gene with an
effect comparable with APOE. SUCLG2 explained 10.7% of
the variance in Ab1 – 42 levels in APOE-14 noncarriers, which
is more than the variance explained by APOE-14 in the overall
sample (7.1%, Supplementary Material, Table S5).
None of the presently investigated SNPs showed genome-
wide significant association with pTau181. To date, genome-
wide significant association with total Tau/pTau181 levels has
been reported for four loci, i.e. APOE, SNAR-I, GLIS3 and
NCR2 (1,4,5). Besides APOE, a recent GWAS by Cruchaga
et al. (5) identified the following three novel genome-wide
significant findings for total Tau and pTau181 levels: (i) rs9877502
at SNAR-I, P¼ 4.89 × 1029 and P¼ 1.68 × 1027 for total Tau
and pTau181, respectively; (ii) rs514716 at GLIS3, P¼ 1.07 ×
1028 and P¼ 3.22 × 1029 for Tau and pTau181, respectively and
(iii) rs6922617 at NCR2, P¼ 2.55 × 1025 and P¼ 3.58 × 1028
for total Tau and pTau181, respectively. Of these three SNPs, only
rs9877502 and pTau181 showed a nominally significant association
in the present GWAS meta-analysis of pTau181 (P¼ 9.21 × 1024).
Interestingly, we observed a non-significant trend for rs6922617
(P¼ 0.07). This locus received further support from the adjacent
SNP rs11966476 (P ¼ 0.04) (Supplementary Material, Table S3).
We observed a nominally significant association between
the pTau181 level and three SNPs: rs429358 (APOE locus),
rs9877502 (SNAR-I) and rs11966476 (NCR2). To our knowledge,
our results for SNAR-I and NCR2 represent the first independentT
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replications of these loci. A possible reason for our failure to rep-
licate the finding for GLIS3 is that in addition to AD dementia
patients, the study by Cruchaga et al. also included MCI patients
and controls. If GLIS3 only contributes to pTau181 variance in
unaffected individuals or during the preclinical stages of
disease, this effect may not be present in our sample.
With the exception of APOE, none of the known AD suscep-
tibility genes showed genome-wide significant association with
either Ab1 – 42 or pTau181 levels in the present study. Previous
studies have reported associations between Ab1 – 42 or pTau181
levels and the AD susceptibility genes PICALM, CLU,
MS4A4A and TREM2 (2,3,5). Again, our failure to replicate
these findings, even at a level of nominal significance, may
have been due to the fact that our study focused on AD dementia
patients only. The present study is the first to report an associ-
ation between the AD susceptibility gene CD2AP (rs9349407)
and pTau181 level (P ¼ 0.031), although this finding was only
nominally significant and requires replication. In the case of
TREM2, a genuine association between the SNP originally asso-
ciated with AD (rs75932628; p.R47H) and pTau181 cannot be
ruled out, since none of the present SNPs in this region displayed
sufficient linkage disequilibrium with rs75932628, and this SNP
cannot be imputed adequately using available variant databases.
SUCLG2 encodes a GTP-specific b-subunit of the succinyl-
CoA ligase (SUCL). The mitochondrial matrix enzyme SUCL
is a heterodimer, which is formed by an invariable a-subunit
(encoded by SUCLG1), and a variable b-subunit which
confers nucleoside specificity. This b-subunit is encoded by
either SUCLA2 or SUCLG2. In the case of SUCLG2, the
SUCL enzyme catalyzes the reversible conversion of succinyl-
CoA and GDP to succinate and GTP, respectively (8). Previous
studies have identified mutations in SUCLG1 and SUCLA2 in
patients with mitochondrial DNA (mtDNA) depletion syn-
dromes (MDS). MDS are characterized by a decrease in
mtDNA content and a reduction in the activity of mitochondrial
respiratory chain complexes I, II, IV and V (9). Interestingly,
both features have also been found, to a lesser extent, in AD
(10). In line with this, Miller et al. demonstrated that reducing
the expression of SUCLG2 led to a decrease in both mtDNA
and the activity mitochondrial complex IV (11).
Our observation of higher SUCLG2 expression in APOE-14
noncarriers may be explained in terms of the amyloid cascade
hypothesis. While hereditary AD is caused by an overproduction
of Ab1 – 42 secondary to autosomal dominant mutations in genes
coding for APP and presenilin 1 and 2, sporadic AD is more
likely to arise from limited clearance of Ab1 – 42 (12). Limited
clearance by microglia is likely to contribute to increased
Ab1 – 42 burden in the brains of sporadic AD dementia patients,
as described recently for the CD33 risk allele rs3865444 (13).
In terms of the interaction of APOE with SUCLG2, an improve-
ment in the microglial clearance of Ab1 – 42 may be of central
importance in terms of explaining this genetic relationship.
In this regard, ApoE is indeed tightly connected to the turnover
of Ab1 – 42, since it plays a critical role in the normal proteolytic
clearance of Ab1 – 42 (14). Increased levels of ApoE and lipida-
tion of ApoE increase the intra- and extracellular microglial deg-
radation of Ab1 – 42 by increasing the interaction between ApoE
and Ab1 – 42 (15). Notably, ApoE-12 and 13 isoforms have a
higher lipidation status than the ApoE-14 isoform, and ApoE-14
is much less efficient in promoting soluble Ab1 – 42 degradationT
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by microglia (14). In the present study, the association between
rs62256378 and Ab1 – 42 CSF levels was modified by ApoE-14.
The latter also decreased the level of SUCLG2 in microglia, and
this in turn impaired Ab1 – 42 phagocytosis. Conversely, in AD
patients carrying the SUCLG2A allele and beingAPOE-14 non-
carriers, microglial Ab1 – 42 clearance is probably improved
through the combination of two mechanisms. First, an ApoE-
dependent mechanism that delivers more efficiently Ab1 – 42 to
microglia. Second, microglia of these AD patients can more
efficiently phagocyte Ab1 – 42. Removal of Ab1 – 42 by microglia
is likely to decrease the propensity of Ab1 – 42 to aggregate and
deposit. In AD patients, the levels of Ab1 – 42 in the CSF are
lowered quite early after clinical disease onset or possibly
even before (16). This is explained by the intrinsic tendency of
Ab1 – 42 to form aggregates ranging from soluble oligomers to
ultimately insoluble senile plaques. Since this process is posi-
tively correlated with the concentration of Ab1 – 42 in the brain
parenchyma, decreased degradation of Ab1 – 42 will increase
the concentration of Ab1 – 42 and concomitantly its tendency to
form aggregates. As a consequence of this process, the amount
of Ab1 – 42 that is available to escape into the CSF is lowered.
Therefore, stabilized SUCLG2 levels and concomitant micro-
glial clearance may maintain higher Ab1 – 42 CSF levels by redu-
cing the tendency of Ab1 – 42 to aggregate in the brain.
Furthermore, microglial function may also be of relevance to
cognitive performance, as suggested by recent experimental
data, which showed that improved microglial clearance was pro-
tective in terms of memory function (17). A plausible hypothesis
is that improved microglial function may account for the stabil-
ization of MMSE scores in rs62256378-A carriers. These find-
ings are consistent with a number of previous reports, which
have implicated innate immune activation and microglial clear-
ance in sporadic AD.
Microglial phagocytosis of Ab1–42 is highly energy dependent,
andmostof thisenergy isprovidedbymitochondria.Alternatively,
the effect of SUCLG2 on microglial clearance of Ab1–42 may
be mediated by modulation of oxidative stress and inflammation.
The latter is involved in Ab1–42 clearance in the brain, in which
microglia participate actively by internalizing and degrading
soluble (18) and aggregated forms of Ab1–42 (19). On the other
hand, microglia have been identified as an important source of re-
active oxygen species (ROS) (20). The mitochondrial respiratory
chain is a major source of ROS. The association between inflam-
mation and oxidative damage is mediated by the release of ROS
during the inflammatory process. In old transgenic AD mice,
microglial function is impaired, as shown by the decrease
expression of Ab1 – 42-binding receptors and Ab1 – 42-degrading
enzymes, whereas microglia maintain their ability to produce
pro-inflammatory cytokines (21). Thus, a chronic inflammatory
status is produced, which increases oxidative stress and the accu-
mulation of Ab1 – 42 in the brain, and reduces the clearance of
Ab1 – 42. In addition, reducing oxidative stress in transgenic
AD mice has been shown to diminish amyloid plaque burden
and microglial activation (22). The maintenance of mtDNA is
crucial for mitochondrial function, since it encodes the key
enzymes of mitochondrial respiration. Hence, the beneficial
effect of the SUCLG2 A allele on the clearance of Ab1 – 42 and
on the clinical course of AD may be mediated by improved
respiratory chain and mtDNA maintenance, a compensatory
mechanism which enhances mitochondrial function by reducingT
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microglial oxidative stress and pro-inflammatory activity. This
in turn increases the clearance of Ab1 – 42 and reduces the rate
of neuronal death.
Interestingly, while the evidence for interaction between
SUCLG2 and APOE was strong in terms of the effect on Ab1–42
levels (P ¼ 9.5 × 1025), no such interaction was evident in the
analysis of clinical course (P ¼ 0.456). This may suggest that
SUCLG2 contributes to Ab1 – 42 and clinical course through
(at least partially) independent pathways and that the pathway
leading to variance in clinical course is not—or at least not
strongly—influenced by APOE. This hypothesis is consistent
with the lack of consistent evidence for an association between
APOE genotype and clinical course, despite the very strong
effect of APOE genotype on Ab1 – 42 levels and on disease
susceptibility.
Further studies are now warranted to disentangle the detailed
molecular mechanisms underlying the influence of SUCLG2 on
both Ab1 – 42 levels and disease course.
MATERIALS ANDMETHODS
GWAS samples
GWAS data on the CSF biomarkers Ab1 – 42 and phosphorylated
pTau181 from three independent AD cohorts were analyzed
(Bonn1CSF, n ¼ 113; Bonn2CSF, n ¼ 167; ADNI, n ¼ 83).
All AD dementia patients included in the GWAS analysis ful-
filled NINCDS/ADRDA criteria for probable AD (23). The
demographic data of the GWAS AD dementia patients are
shown in Table 1.
The Bonn1CSF and Bonn2CSF GWAS samples were derived
from a larger German GWAS cohort (n ¼ 1079) which was
recruited from the following three sources: (i) the German
Dementia Competence Network (24) (DCN; n ¼ 391); (ii) the
German study on Aging, Cognition and Dementia in primary
care patients (25) (AgeCoDe, n ¼ 64); and (iii) the interdiscip-
linary Memory Clinic at the University Hospital of Bonn
(n ¼ 624). These German patients were classified as two separ-
ate samples (i.e. Bonn1, n ¼ 438; and Bonn2, n ¼ 641), as they
were genotyped using two different platforms (see below). The
Bonn1CSF and Bonn2CSF samples were comprised of AD
dementia patients from Bonn1 and Bonn2, respectively, for
whom CSF data were available. The Bonn1CSF included 61
patients from the Memory Clinic and 52 from the DCN. The
Bonn2CSF consisted of 84 patients from the Memory Clinic
and 83 from the DCN.
Between 2003 and 2005, the DCN recruited a large cohort of
patients with MCI (n ¼ 1095 patients) or early AD (n ¼ 391).
Baseline analysis comprised extensive neuropsychological
tests including those of the Consortium to Establish a Registry
for Alzheimer’s Disease (CERAD), the MMSE and the Clinical
Dementia rating (CDR-SB). Follow-up assessments were per-
formed at 12 and 24 months (24). Whole blood, genomic
DNA, plasma and CSF were collected from all participants.
AgeCoDe is a German multicenter prospective cohort study.
The sample was drawn at random from general practice regis-
tries in six German cities, and the selected individuals were
contacted by mail. Main inclusion criteria were age 75 years or
above and the absence of dementia according to the clinical judg-
ment of the respective general practitioner. A total of 3327T
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AgeCoDe participants were recruited between January 2002 and
November 2003 (25,26). Each participant is assessed at baseline
and at 18 months intervals thereafter. All assessments are per-
formed at the participant’s home by a trained study psychologist
or physician. At all visits, assessment includes the Structured
Interview for Diagnosis of Dementia of Alzheimer type, Multi-
Infarct Dementia and Dementia of other etiology according to
DSM-IV and ICD-10 (SIDAM) (27). The SIDAM comprises:
(i) a 55-item neuropsychological test battery, including all 30
items of the MMSE and assessment of several cognitive
domains (orientation, verbal and visual memory, intellectual
abilities, verbal abilities/ calculation, visual–spatial construc-
tional abilities and aphasia/ apraxia); (ii) a 14-item scale for
the assessment of the activities of daily living (SIDAM-ADL-
Scale) and (iii) the Hachinski Rosen Scale. Dementia was diag-
nosed according to DSM-IV criteria. The AgeCoDe study was
approved by all of the respective ethics committees. Written
informed consent was obtained from all study participants or
their legal guardians. At the time of writing, four waves of
follow-up have been completed in the AgeCoDe cohort.
The interdisciplinary Memory Clinic of the Department of
Psychiatry and Department of Neurology at the University
Hospital in Bonn provided further patients (n ¼ 624). Diagnoses
were assigned according the NINCDS/ADRDA criteria (23) and
on the basis of clinical history, physical examination, neuro-
psychological testing (using the CERAD neuropsychological
battery, including the MMSE), laboratory assessments and
brain imaging.
The third GWAS sample was a subsample of the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) cohort. This com-
prised 83 AD dementia patients of non-Hispanic Caucasian
origin for whom CSF biomarker data were available. The
ADNI is a $60 million, 5-year public-private partnership
which was launched in 2003 by the National Institute on
Aging, the National Institute of Biomedical Imaging and Bio-
engineering, the Food and Drug Administration and various
private pharmaceutical companies and non-profit making orga-
nizations. The Principal Investigator of this initiative is Michael
W. Weiner, MD. ADNI is the result of the efforts of many coin-
vestigators from a broad range of academic institutions and
private corporations, and subjects have been recruited from
over 50 sites across the USA and Canada. The initial goal of
ADNI was to recruit 800 adults aged 55–90 years, i.e. 200 cog-
nitively normal individuals for 3-year follow-up, 400 individuals
Figure 2. Functional studies of SUCLG2. (A and B) SUCLG2 localized to microglia in AD brains. (A) Representative DAB immunostaining with SUCLG2 and
HLA-DR (as a human microglial marker) in brain cortex of AD subjects. DAB-positive cells with characteristic romboidal nuclei (typically microglial cells) are indi-
cated by arrows. Scale bars are 100 and 20 mm on the main and small images, respectively. (B) High-resolution confocal image of an area of frontal cortex from an AD
dementia patient immune labelled with HLA-DR (green) and SUCLG2 (red). Plaque autofluorescence is visible in the blue channel and it is highlighted with a dis-
continuous line. Most of the SUCLG2 is enclosed by the HLA-DR (arrow). The top panel shows several viewpoints of a 3D reconstruction of the same area, which is
shown in the lower panel. (Scale is 10 mm.) (C) Increased levels of SUCLG2 in AD ApoE 3/3 brains. Soluble extracts from postmortem frontal cortex of AD dementia
patients with ApoE 3/4 and ApoE 3/3 status plus age-matched healthy controls (CN) were probed with an antibody to SUCLG2. Expression levels were normalized to
Hsp75 (CN, n ¼ 6; AD, 3/4, n ¼ 8; AD, 3/3, n ¼ 4). Data are presented as mean+SEM. Asterisk denotes P, 0.05. (D) SUCLG2 silencing is detrimental to extra-
cellular Ab1 – 42. FAM-Ab1 – 42 phagocytosis was impaired in BV2 cells in which SUCLG2 was silenced by two distinct siRNA compared with negative control siRNA
(n ¼ 6). FAM-Ab1 – 42 was added at a 500 nM final concentration and the amount of internalized Ab1 – 42 was assessed at the indicated time points, showing that cells
contain less Ab1 – 42 in the absence of SUCLG2. Data are presented as mean+SEM. Asterisk denotes P , 0.05.
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with MCI for 3-year follow-up and 200 individuals with early
AD for 2-year follow-up. Up-to-date information on the cohort
is available at www.adni-info.org. All AD dementia patients ful-
filled NINCDS/ADRDA criteria (23), and their magnetic reson-
ance imaging (MRI) data were consistent with this diagnosis.
ADNI participants undergo evaluation at 6- to 12-month inter-
vals through a battery of assessments including cognitive
and neuropsychological testing, neuroimaging (MRI with or
without positron emission tomography) and measurement of
plasma and CSF biomarkers. Among other instruments, cogni-
tive status is assessed using the MMSE score. The ADNI study
is approved by the Institutional Review Board at each of the par-
ticipating centers, and all participants provide written informed
consent. Data used in the preparation of the present study were
obtained from the ADNI database.
Replication sample
These patients were drawn from the ongoing memory-clinic-
based ADC of the VU University Medical Center. All patients
underwent a standardized 1-day assessment, comprising medi-
cal history, informant based history, physical and neurological
examination, laboratory tests, neuropsychological assessment
and brain MRI. Probable AD diagnoses were assigned according
to both NINCDS/ADRDA criteria (23), and the core clinical
NIA-AA criteria (28). Follow-up took place during routine clin-
ical attendance at the memory clinic, and involved patient
history, cognitive testing including the MMSE, and a general
physical and neurological examination. Patients who failed to
attend routine follow-up for at least 2 years after baseline were
contacted by telephone, and their cognitive status was evaluated
using a standardized interview that included questions concern-
ing all cognitive domains, physical complaints and medical
history, complemented by the Telephone Interview for Cogni-
tive Status (29). In cases where the telephone interview sug-
gested clinical progression, patients underwent a detailed
evaluation at the outpatient clinic.
Investigation of rs62256378 in AD risk
A case–control sample was used to investigate whether
rs62256378 confers AD risk. The AD dementia patients were
derived from the Bonn1 and Bonn2 samples (n ¼ 1079). The
control sample was mainly comprised of individuals from
three population-based studies: the Heinz Nixdorf Recall
(HNR) study cohort (n ¼ 1188) (30), the POPGEN biobank
(n ¼ 471) (31) and the KORA study (n ¼ 458) (32). These con-
trols were not screened for cognitive impairment. Furthermore,
287 healthy elderly individuals from the AgeCoDe cohort, in
whom dementia and MCI had been excluded at the last follow-up
visit, were also included. The demographic data for these
samples are provided in Table 1. In addition, Stage I association
results for rs62256378 were obtained from a case–control
meta-analysis study conducted by the IGAP (6). In Stage I of
this meta-analysis 17 008 AD cases and 37 154 controls were
analyzed. In addition, APOE-14 carrier–noncarrier stratified
association results were obtained from the IGAP.
Investigation of rs62256378 in cognitive decline
The effect of rs62256378 on cognitive decline in AD dementia
patients was explored using longitudinal MMSE scores in AD
dementia patients from: the Bonn1 (n ¼ 80), Bonn2 (n ¼ 110),
ADNI (n ¼ 140) and the ADC (n ¼ 339). The effect of
APOE-14 carrier–noncarrier status on the rs62256378 effect
on MMSE progression was also analyzed.
CSF collection and analysis
For the Bonn1CSF and Bonn2CSF samples, diagnostic lumbar
punctures were performed at the respective Department of Neur-
ology or Psychiatry using a standardized technique. The subject
was placed in a sitting or supine position, and a 22G atraumatic
spinal needle was inserted. The CSF samples were kept on ice for
a maximum of 1 h and then centrifuged for 10 min (2000 g at
48C). Samples were aliquoted to 0.25 ml and stored in polypro-
pylene tubes at2808C until analysis. All CSF samples were sent
to the Department of Psychiatry in Erlangen for quantification.
Levels of Ab1–42 and pTau181 were measured using commercially
available ELISA immunoassays INNOTESTw b-amyloid(1–42)
and INNOTESTw PhosphoTAU(181p) (Innogenetics), in accord-
ance with the protocols described by Popp et al. (33).
In the ADNI cohort, lumbar puncture was performed using a
20G or 24G spinal needle, as described in the ADNI procedures
manual. In brief, CSF was collected into collection tubes pro-
vided to each site. The CSF samples were then transferred into
polypropylene transfer tubes and placed on dry ice within 1 h
of collection. They were then shipped overnight to the ADNI
Biomarker Core Laboratory at the University of Pennsylvania
Medical Center on dry ice. After thawing for 1 h at room tem-
perature and gentle mixing, aliquots (0.5 ml) of these samples
were prepared. The aliquots were stored in bar code-labelled
polypropylene vials at 2808C. CSF levels of Ab1 – 42 and
pTau181 were measured using the multiplex xMAP Luminex
technology (Luminex Corp) and INNO-BIA AlzBio3 immu-
noassays (Innogenetics) according to protocols described else-
where (1).
In the ADC cohort, lumbar puncture was performed using a
25G needle. The CSF was collected in polypropylene tubes
and centrifuged at 1800 g for 10 min at 48C. The CSF was imme-
diately stored at 2208C until further analysis (maximum
2 months). CSF levels of Ab1 – 42 and pTau181 were measured
using similar commercial ELISA immunoassays to those used
for Bonn1CSF and Bonn2CSF. Quantification was performed
in the neurological laboratory of the VU University Medical
Center in Amsterdam in accordance with the protocols described
by Mulder et al. (34).
Standardization of CSF biomarker levels was necessary since
values in the ADNI cohort differed substantially from those
observed in the Bonn1CSF, Bonn2CSF and ADC cohorts, due
to the different platforms used (regular ELISA versus
Luminex). Individual CSF levels were standardized within
each study using a standard normal transformation. In all four
cohorts, the CSF biomarkers Ab1 – 42 and pTau181 data showed
a normal distribution (Supplementary Material, Figs S1 and S2).
6654 Human Molecular Genetics, 2014, Vol. 23, No. 24
Genotyping
The Bonn1CSF sample was genotyped on the Illumina 610-quad
chip, and was part of the sample investigated by Harold et al.
(35). The Bonn2CSF sample was genotyped using the Illumina
Omni 1M-quad chip. The ADNI cohort was genotyped using
the Illumina 610 chip.
The control sample of Bonn1 was genotyped using the Illu-
mina HumanHap550k chip. The control sample of Bonn2 was
genotyped with the Illumina 1M-quad chip.
Genotyping in the ADC sample was performed using the Mas-
sArray system and a Sequenom Compact MALDI-TOF device
(Sequenom). SNPs were selected for the replication step if
they modulated either Ab1 – 42 or pTau181 with a P-value of
,5 × 1026 and showed consistent allele direction across all
three GWAS. A total of 163 SNPs representing 36 novel loci
met these criteria. Successful Sequenom assay design was
achieved for 40 SNPs. These included rs429358, which charac-
terizes APOE-14 versus APOE-14 noncarriers, and 30 SNPs
representing 29 potentially novel loci. For seven of the 36
novel loci, design of a Sequenom assay failed due to technical
reasons and a lack of additional proxies for the respective
locus. SNPs representing the nine other known AD susceptibility
genes were also included (Supplementary Material, Table S1)
(35–38). Primer sequences and assay conditions are available
upon request. Thus, a total of 40 SNPs were genotyped in the
ADC cohort.
Since rs62256378 was imputed in the GWAS step, the
SNP was genotyped directly in GWAS patients for whom
DNA was available using Sequenom (Bonn1CSF, n ¼ 112 and
Bonn2CSF, n ¼ 152).
Quality control
The Bonn1 sample was part of the sample investigated by Harold
et al. (35) which comprised 19 000 samples prior to QC. Follow-
ing stringent QC, Harold et al. eliminated 53 383 SNPs and 2850
subjects from their data analysis. No German subjects were
excluded. For the present analyses, a check was made for devia-
tions from Hardy–Weinberg equilibrium within the German
subgroup, and 55 SNPs with an HWE P , 1026 were excluded.
In the Bonn2 sample, seven individuals were excluded due to
potential relatedness, as indicated by high genome-wide
identity-by-state values (4 SDs greater than overall mean IBS).
SNPs with a genotyping rate of,99% were excluded. Four indi-
viduals were also excluded due to a genotyping rate of ,99%.
Finally, 88 SNPs were excluded due to deviation from HWE
(P , 1026), and 80 000 SNPs due to low MAF (,1%). The
QC criteria used for Bonn2 were applied to the entire ADNI
cohort. In total, 24 individuals and 42 199 SNPs were excluded
due to a low genotyping rate, 80 SNPs due to deviation from
HWE, and 5961 SNPs due to low MAF.
The QC procedure applied to the population-based Bonn1
controls is described elsewhere (39). In this sample, 49 controls
were removed due to a low genotyping rate. In addition, 80 con-
trols were removed because they overlapped with the HNR
control sample used in Bonn2.
In the ADC replication cohort, three samples were excluded
due to a genotyping rate of ,95%. In addition, 101 individuals
were excluded because their covariate APOE status was
unavailable. A total of five SNPs were excluded due to a low
genotyping rate (,95%), strong deviation from HWE
(P ¼ 1 × 10238) or monomorphic status (Supplementary
Material, Table S1).
Statistical analyses
For each of the three GWAS (Bonn1CSF, Bonn2CSF and
ADNI), genotype data were imputed using the 1000 Genomes
(40) reference data, May 2012 release, and the IMPUTEv2 soft-
ware package (41). Imputed SNPs with an information score of
,0.4 or an MAF of ,3% were excluded. Imputation accuracy
was satisfactory, with info scores of 0.61, 0.67 and 0.75, in
Bonn1CSF, Bonn2CSF and ADNI, respectively. After imput-
ation, a total of 6 812 394 SNPs were included in the initial
GWAS step and the meta-analysis of the three GWAS. A com-
plete (genome wide) set of summary association statistics for
both Ab1–42 and pTau181 were deposited at http://intersnp.meb.
uni-bonn.de/CSF_AD.html.
To identify possible stratification within each cohort, a multidi-
mensional scaling analysis was performed using PLINK (42). The
three leading principal components were retained as covariates.
In each cohort, CSF levels were analyzed as quantitative traits
(QTs) using an additive allelic linear regression model, as imple-
mented in PLINK. Age, sex and APOE status—as defined by the
number of APOE-14 copies—were additional covariates.
The association results were combined in a meta-analysis using
the fixed effects model (43), as implemented in YAMAS (44). In
addition, heterogeneity measures (45) were computed and meta-
analysis was performed under a random effects model (43). Sig-
nificance of cross-study differences in the b estimates for rs622
56378 was assessed using the x2-test for heterogeneity.
GWAS generated genome-wide inflation factors for Ab1 – 42
of l ¼ 1.012 in Bonn1CSF, l ¼ 1.005 in Bonn2CSF and
l ¼ 1.05 in ADNI. For pTau181, GWAS produced genome-wide
inflation factors of l ¼ 1.006 in Bonn1CSF, l ¼ 1.013 in
Bonn2CSF and l ¼ 1.001 in ADNI. The meta-analysis of the
three GWAS data yielded genome-wide inflation factors of
l ¼ 1.05 and 1.03 for Ab1 – 42 and pTau181, respectively (Sup-
plementary Material, Fig. S3). Therefore, we decided to
present l-adjusted P-values for the genome-wide analysis
instead, and to validate any particular potentially genome-wide
significant findings via Monte-Carlo simulation.
The experimental genotypes of the replication ADC cohort
were analyzed with INTERSNP (46), and combined with the
GWAS results in the meta-analysis fashion described above.
The explained variance was determined using the coefficient
of determination R2 of the linear regression model without the
covariates that were used for P-value computation.
Two SNPs showing association with Ab1 – 42 level were repli-
cated in the ADC, i.e. rs429358 at the APOE locus and
rs62256378 at a novel locus containing the SUCLG2 gene.
A possible genetic interaction between these two association
signals was explored as an indicator of a possible biological
link. For this, SNP–SNP interaction was analyzed using an
allelic interaction test (one degree of freedom test, 1 d.f.). The
standard genotype coding and definition of interaction para-
meters provided by Cordell and Clayton (47) were used, as
implemented in INTERSNP.
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Case–control analysis was performed using a standard logis-
tic regression test (1 d.f.). Cognitive decline was computed as
DMMSE/Dt, where DMMSE was the difference in the MMSE
scores between time point A and time point B, and where Dt
was the time in days between time points A and B. DMMSE/Dt
was then analyzed as a QT. Educational status and MMSE at
time point A were used as additional covariates.
Human brain tissue
Postmortem human brain tissue specimens from patients with
histologically confirmed AD and from age-matched controls
who had died from non-neurological disease (75+ 10 years at
the age of death) were obtained from the Neurological Tissue
Bank of the Biobank from the Hospital Clinic-Institut d’Investi-
gacions Biome`diques August Pi i Sunyer in Barcelona. Post-
mortem duration varied from 1.5 to 5 h; neither age nor
postmortem sampling time differed significantly between con-
trols and AD dementia patients.
Immunohistochemistry
For colocalization of SUCLG2 in human brain cortex, tissue sec-
tions were subjected to paraffin removal at 608C for 30 min,
xylene treatment and rehydration through a graded ethanol
series. Antigen unmasking was performed by heating the
tissue sample to 1008C for 20 min in 10 mM sodium citrate
buffer (pH ¼ 6). Sections were incubated with rabbit anti-
SUCLG2 antibody (Novus Biologicals, NBP1-32521) diluted
to 1 : 400 and mouse anti-HLA-DR (Thermo scientific,
MA1-35420) diluted to 1 : 100. Consecutive sections were
further incubated with biotinylated secondary antibody, and
signal amplification was achieved with HRP–streptavidin–
biotin conjugates (Vectastain Elite ABC system). Diaminoben-
zidine (DAB)-stained sections were then counterstained with
hematoxylin. Brightfield images were then obtained using an
axioplan microscope (Zeiss). In parallel, sections were incu-
bated with Alexa 488 and Alexa 546-conjugated secondary anti-
bodies and mounted on a dapi-containing mounting media
(Vectorlabs). An attempt was made to quench autofluorescence.
Hi-Res confocal images were obtained using a Leica SP5 Laser
Scanning Confocal Microscope (Leica). Following deconvolu-
tion, 3D reconstruction was performed using Huygens Scientific
Volume Imaging.
Cell culture and transfection
BV2 murine microglial cells were obtained from the American
Type Culture Collection. The cells were maintained at 378C in
5% CO2 DMEM medium, supplemented with 10% fetal calf
serum and 1% penicillin/streptomycin. The following were
obtained from Invitrogen: three different Stealth siRNA directed
to exons 4, 5 and 6–7 of SUCLG2 (5′-GCGGUUUGAAAGGA
GGUGUUCAUU-3′, 5′-CCCUGGAUAUUUCUAGAGAAA
CAUA-3′ and 5′-ACCAGGCUGCAGAUCAGAUUACAAA-3′);
the recommended Stealth negative control; and the positive
(GAPDH) control siRNA duplexes. Transfections were per-
formed using lipofectamine 2000 (Invitrogen) in accordance
with the manufacturer’s recommendations.
Western blot
Protein extracts from BV2 cells or frozen human brain tissue
were homogenized in TNE buffer (10 mM Tris–HCl, pH 7.4;
150 mM NaCl, 5 mM EDTA; 0.5% NP-40; 1× complete protease
inhibitor cocktail (Roche); 1× phosphatase inhibitor cocktail I
and II (Sigma–Aldrich). Protein concentration was determined
using the BCA method (Pierce Biotechnology). A total of
20 mg of protein was resolved by SDS–PAGE, transferred to
PVDF and probed with rabbit anti-SUCLG2 antibody (Novus
Biologicals, NBP1-32521) diluted to 1 : 500. Following over-
night incubation, the membranes were rinsed three times in
TTBS and incubated at 228C in 800CW donkey anti-rabbit sec-
ondary antibody in 5% nonfat milk in TTBS, pH ¼ 7.5. The blots
were visualized using an LI-COR Biosciences Odyssey infrared
imaging system (Lincoln). After visualization, the blots were
stripped through rinsing with TBS. They were then incubated
at 558C for 30 min in a buffer containing 200 mM glycine, 2%
SDS and 100 mM mercaptoethanol. Membranes were rinsed in
TBS and then blocked and reprobed with mouse monoclonal
anti-Hsp75 (UC David/NIH NeuroMab Facility, clone N52A/
42) diluted to 1 : 1000; rinsed three times in TTBS; incubated
at 228C in 800CW donkey anti-mouse secondary antibody in
5% nonfat milk in TTBS, pH ¼ 7.5; and visualized using the
LI-COR system (Lincoln).
Phagocytosis of FAM-labeled Ab1–42 (FAM-Ab1–42)
Following incubation of Ab1 – 42 at 378C for 3 days, microglial
phagocytosis of aggregated FAM-Ab1 – 42 (Anaspec) was mea-
sured using a plate-based assay. Control or SUCLG2-silenced
BV2 cells were plated at 50 000 cells per 100 ml in black
96-well plates, and FAM-Ab1 – 42 was added to a final concentra-
tion of 500 nM and incubated for 0, 2 or 4 h. The FAM-Ab1 – 42-
-containing medium was then removed and the remaining
extracellular FAM-Ab
1 – 42
was quenched for 1 min with 100 ml
0.2% trypan blue in PBS, pH ¼ 4.4. Following aspiration, fluor-
escence was measured at 485 nm excitation/535 nm emission
using an Infinite 200 reader (Tecan). To normalize for cell
numbers, 100 ml at 50 mg/ml Hoechst Dye 33342 in PBS was
added and the sample was incubated for 30 min. Fluorescence
was measured at 360 nm excitation/465 nm emission using the
Infinite 200 reader (Tecan). In addition, microglial FAM-Ab1–42
phagocytosis was verified by confocal microscopy using a BX61
microscope equipped with a disc-spinning unit (Olympus).
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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